Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
PR Newswire•02/11/2026•07:00 ET
0
Key Highlights
- ➤RHB-204 demonstrated MAP-killing capability comparable to RHB-104 in two in vitro assay sets
- ➤RHB-204 matched RHB-104 across MAP strains from human patients and animal carriers
- ➤RHB-204 achieved comparable MAP killing with lower doses of two active ingredients
- ➤RHB-104 plus standard of care was 64% more effective than standard of care alone
- ➤RHB-204 is Phase 2-ready for MAP-positive Crohn’s disease evaluation
Expert Statements
Tim Bull, Professor of Cell and Molecular Biology, City St George’s University of London
“RHB-204 demonstrated a significant MAP-killing effect, similar to RHB-104, against multiple strains of MAP, both human and animal, whilst intracellularly persistent. MAP is remarkably difficult to kill and test against due to its unique biological structure, intracellular lifestyle, and slow growth rate. This data gives a valuable insight into the potential of RHB-204 to treat MAP-related Crohn’s disease involving either human or animal derived MAP strains.”
Reza Fathi, Senior VP, R&D at RedHill
“We know from previous published positive Phase 3 clinical testing that RHB-104 delivered a statistically significant 64% improvement over placebo in efficacy in treating Crohn’s disease using a MAP-targeted approach. In vitro confirmation of RHB-204’s MAP-killing effect and comparability to RHB-104 is another step forward in the development of RHB-204 for MAP-related CD”
Reza Fathi, Senior VP, R&D at RedHill
“We believe Phase 2-ready RHB-204 could be among the first treatments to be evaluated in an adequately controlled study in a specifically defined MAP-positive Crohn’s disease patient population.”
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate PR Newswire
In vitro studies, undertaken by two leading microbiology centers, confirm RHB-204's killing capability on Mycobacterium avium subspecies paratuberculosis (MAP) and its MAP-killing comparability to RedHill's RHB-104 in both long-term intracellular culture and spot and phage assays
Get started
Create a free account to read the full story.